<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Aggressive glycemic control has been hypothesized to prevent <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A systematic review was conducted to summarize the benefits of intensive vs conventional <z:chebi fb="105" ids="17234">glucose</z:chebi> control on kidney-related outcomes for adults with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Three databases were systematically searched (January 1, 1950, to December 31, 2010) with no language restrictions to identify randomized trials that compared surrogate renal end points (<z:mp ids='MP_0002959'>microalbuminuria</z:mp> and macroalbuminuria) and clinical renal end points (doubling of the serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> level, <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>], and <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e>) in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> receiving intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control vs those receiving conventional <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We evaluated 7 trials involving 28 065 adults who were monitored for 2 to 15 years </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with conventional control, intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control reduced the risk for <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (risk ratio, 0.86 [95% CI, 0.76-0.96]) and macroalbuminuria (0.74 [0.65-0.85]), but not doubling of the serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> level (1.06 [0.92-1.22]), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> (0.69 [0.46-1.05]), or <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> (0.99 [0.55-1.79]) </plain></SENT>
<SENT sid="5" pm="."><plain>Meta-regression revealed that larger differences in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c between intensive and conventional therapy at the study level were associated with greater benefit for both <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and macroalbuminuria </plain></SENT>
<SENT sid="6" pm="."><plain>The pooled cumulative incidence of doubling of the serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> level, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, and <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> was low (&lt;4%, &lt;1.5%, and &lt;0.5%, respectively) compared with the surrogate renal end points of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (23%) and macroalbuminuria (5%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control reduces the risk for <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and macroalbuminuria, but evidence is lacking that intensive glycemic control reduces the risk for significant clinical renal outcomes, such as doubling of the serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> level, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, or <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> during the years of follow-up of the trials </plain></SENT>
</text></document>